Direct Comparison of Kesimpta and Gilenya Effectiveness
Kesimpta (ofatumumab) and Gilenya (fingolimod) both treat relapsing forms of multiple sclerosis (RMS), but head-to-head trials are absent, so effectiveness draws from separate phase 3 studies against similar benchmarks like Avonex (interferon beta-1a). Kesimpta showed superior annualized relapse rate (ARR) reduction of 50-59% versus Avonex, alongside 83% fewer Gd+ T1 lesions on MRI.[1][2] Gilenya achieved 48-54% ARR reduction and 82% fewer Gd+ T1 lesions versus Avonex or placebo.[3][4] Real-world data and indirect meta-analyses suggest Kesimpta edges out Gilenya in ARR reduction (e.g., 0.11 vs. 0.18 relapses/year) and confirmed disability progression (CDP) risk, though differences are modest and not always statistically significant.[5][6]
How They Work and Target MS Activity
Kesimpta, a CD20 monoclonal antibody, depletes B cells via self-injection every 4 weeks after loading doses, rapidly reducing relapses and new lesions.[1] Gilenya, an S1P receptor modulator taken daily as a pill, traps lymphocytes in lymph nodes to curb inflammation, effective for RMS but less so on B-cell driven activity.[3] Kesimpta's B-cell focus may explain stronger no-evidence-of-disease-activity (NEDA) rates in some analyses (up to 80% at 2 years vs. Gilenya's 50-60%).[7]
Key Trial Data Side-by-Side
| Metric | Kesimpta (ASCLEPIOS I/II) | Gilenya (FREEDOMS/DEFINE) |
|--------|----------------------------|-----------------------------|
| ARR | 0.10-0.11 | 0.18-0.20 |
| Gd+ Lesions Reduction | 97-99% | 82-87% |
| 6-month CDP Risk | 0.11-0.15 HR | 0.23-0.28 HR |
| NEDA-3 (2 years) | ~70-80% | ~50-60% |[1][2][3][4][7]
Kesimpta performs better on MRI and NEDA endpoints; Gilenya holds up on brain volume loss in long-term extensions.[8]
What About Progression and Long-Term Outcomes?
Kesimpta slows 12-month CDP more effectively (HR 0.60-0.66 vs. active comparators) than Gilenya (HR 0.70-0.80), per network meta-analyses, with less brain atrophy.[6][9] Both reduce relapses similarly in first-line use, but Kesimpta sustains benefits longer in switchers from other therapies.[10]
Safety and Switching Considerations
Kesimpta has fewer serious infections than Gilenya (0.7% vs. 2-4% herpes zoster risk) but carries infusion-like reaction risks early on.[1][3] Gilenya requires first-dose cardiac monitoring and baseline lymphocyte checks. Patients switching from Gilenya to Kesimpta often see relapse drops within months, per observational studies.[10] Effectiveness edge favors Kesimpta for highly active RMS, but individual factors like PML risk (higher with Gilenya) or convenience (injection vs. pill) matter.[11]
Who Gets Prescribed What and Cost Factors?
Neurologists favor Kesimpta for B-cell depletion needs or injection preference, Gilenya for oral convenience in milder RMS. Kesimpta lists ~$6,000/month; Gilenya generics now ~$100-500/month, improving access.[12] Patents: Gilenya's core expired 2019 (generics entered 2022); Kesimpta's key U.S. patent runs to 2031, per DrugPatentWatch.[13]
Sources
[1]: New England Journal of Medicine - ASCLEPIOS
[2]: Lancet Neurology - ASCLEPIOS
[3]: NEJM - FREEDOMS
[4]: NEJM - DEFINE
[5]: Multiple Sclerosis Journal - Meta-analysis
[6]: Neurology - NMA
[7]: ECTRIMS 2022 Abstracts
[8]: TRANSFORMS Extension
[9]: JAMA Neurology - NMA
[10]: MSBase Registry Data
[11]: FDA Labels (Kesimpta); Gilenya
[12]: GoodRx Pricing
[13]: DrugPatentWatch - Kesimpta